Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2024 Mar;59(6):797-798.
doi: 10.1111/apt.17907.

Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels-authors' reply

Naim Alkhouri  1 , Leo Tseng  2 , Kemal Balic  2 , Hank Mansbach  2 , Maya Margalit  3
Affiliations
Comment

Letter: Severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels-authors' reply

Naim Alkhouri et al. Aliment Pharmacol Ther. 2024 Mar.
No abstract available

PubMed Disclaimer

Comment on

References

REFERENCES

    1. Geladari E, Alexopoulos T, Vasilieva L, Tenta R, Kontogianni M, Alexopoulou A. Letter: severe underweight and sarcopenia in decompensated cirrhosis are associated with high FGF21 levels. Aliment Pharmacol Ther. 2024;59:795-796.
    1. Loomba R, Lawitz EJ, Frias JP, Ortiz-LaSanta G, Johansson L, Franey BB, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol. 2023;8(2):120-132.
    1. Alkhouri N, Lazas D, Loomba R, Frias JP, Feng S, Tseng L, et al. Clinical trial: effects of pegozafermin on the liver and on metabolic comorbidities in subjects with biopsy-confirmed nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2023;58:1005-1015.
    1. Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389(11):998-1008.
    1. Tillman EJ, Rolph T. FGF21: an emerging therapeutic target for non-alcoholic steatohepatitis and related metabolic diseases. Front Endocrinol (Lausanne). 2020;11:601290.

Substances

LinkOut - more resources